NCT02630966 - Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2016

Primary Completion Date

September 4, 2018

Study Completion Date

November 14, 2018

Conditions

Crohn's Disease

Interventions

DRUG

Vedolizumab

Vedolizumab 300 mg IV infusion

DRUG

Placebo

0.9% sodium chloride IV infusion

Trial Locations (18)

20089

Istituto Clinico Humanitas IRCCS, Milan

35033

CHU de Rennes - Hopital de Pontchaillou, Rennes

40138

Azienda Ospedaliera S. Orsola-Malpighi, Bologna

46026

Hospital Universitario y Politecnico La Fe, Valencia

54511

Hopital de Brabois, Vandœuvre-lès-Nancy

59037

CHRU de Lille - Hopital Claude Huriez, Lille

76092

Texas Digestive Disease Consultants, Southlake

98101

Virginia Mason Medical Center, Seattle

37212-1375

Vanderbilt University Medical Center, Nashville

T2N 4Z6

University of Calgary, Calgary

V6Z 2K5

GIRI (GI Research Institute), Vancouver

06202

Hopital l'Archet II, Nice

1105 AZ

Academic Medical Center, Amsterdam

2333 ZA

Leids Universitair Medisch Centrum, Leiden

3015 CE

Erasmus MC, Rotterdam

08036

Hospital Clinic Barcelona, Barcelona

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

OX3 9DU

John Radcliffe Hospital, Oxford